KR20220080045A - 신경보호를 위한 칸나비노이드의 사용을 위한 조성물 및 방법 - Google Patents

신경보호를 위한 칸나비노이드의 사용을 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20220080045A
KR20220080045A KR1020217036628A KR20217036628A KR20220080045A KR 20220080045 A KR20220080045 A KR 20220080045A KR 1020217036628 A KR1020217036628 A KR 1020217036628A KR 20217036628 A KR20217036628 A KR 20217036628A KR 20220080045 A KR20220080045 A KR 20220080045A
Authority
KR
South Korea
Prior art keywords
neuroprotective
neuroprotective compound
composition
compound
neuron
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020217036628A
Other languages
English (en)
Korean (ko)
Inventor
에릭 수
우젠드라 쿠마르
리쉬 쿠마르 솜반쉬
성롱 저우
Original Assignee
인메드 파마슈티컬스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인메드 파마슈티컬스 인코포레이티드 filed Critical 인메드 파마슈티컬스 인코포레이티드
Publication of KR20220080045A publication Critical patent/KR20220080045A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020217036628A 2019-04-24 2020-04-24 신경보호를 위한 칸나비노이드의 사용을 위한 조성물 및 방법 Withdrawn KR20220080045A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962838216P 2019-04-24 2019-04-24
US62/838,216 2019-04-24
PCT/CA2020/050547 WO2020215164A1 (en) 2019-04-24 2020-04-24 Compositions and methods for use of cannabinoids for neuroprotection

Publications (1)

Publication Number Publication Date
KR20220080045A true KR20220080045A (ko) 2022-06-14

Family

ID=72940570

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217036628A Withdrawn KR20220080045A (ko) 2019-04-24 2020-04-24 신경보호를 위한 칸나비노이드의 사용을 위한 조성물 및 방법

Country Status (11)

Country Link
US (1) US20230043428A1 (cg-RX-API-DMAC7.html)
EP (1) EP3958856A4 (cg-RX-API-DMAC7.html)
JP (1) JP7633179B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220080045A (cg-RX-API-DMAC7.html)
CN (1) CN114007603A (cg-RX-API-DMAC7.html)
AU (1) AU2020261515B2 (cg-RX-API-DMAC7.html)
CA (1) CA3134764A1 (cg-RX-API-DMAC7.html)
IL (1) IL287536B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021012960A (cg-RX-API-DMAC7.html)
SG (1) SG11202111809XA (cg-RX-API-DMAC7.html)
WO (1) WO2020215164A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115006404A (zh) * 2022-08-09 2022-09-06 昆药集团股份有限公司 一种具有视神经保护功效的药物组合物及其应用
US20240139272A1 (en) * 2022-10-27 2024-05-02 Kemin Industries, Inc. Use of a spearmint extract for retina neurotrophism
AU2024206205A1 (en) * 2023-01-04 2025-07-17 Florascience Inc. Cannabinoids for use in the treatment of a neurodegenerative disease or condition
IL327899A (en) * 2023-10-23 2026-06-01 Inmed Pharmaceuticals Inc Compositions and methods for use of cannabinol compounds in neuroprotection

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2471987B (en) * 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
BR112013012468A2 (pt) * 2010-11-18 2016-09-06 Pier Pharmaceuticals método de tratar um indivíduo com um distúrbio sensível a canabinóide, de estabelecer uma dose ideal, de tratar um indivíduo com um distúrbio de apneia do sono, e, kit
MX2017005277A (es) * 2014-10-21 2018-01-11 United Cannabis Corp Extractos de cannabis y métodos de preparación y uso de la misma.
MA41299A (fr) * 2014-12-30 2017-11-07 Axim Biotechnologies Inc Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite
US20170266153A1 (en) * 2015-02-27 2017-09-21 Ebbu, LLC Compositions purposefully selected comprising purified cannabinoids and/or purified terpenes
AU2016225026A1 (en) * 2015-02-27 2017-09-07 Canopy Growth Corporation Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral
EP3261629A4 (en) * 2015-02-27 2018-12-05 Ebbu, LLC Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral
US20160282371A1 (en) * 2015-03-28 2016-09-29 Quantalytical Labs Inc. Solid Phase Extraction, Derivatization with Crown Ethers, and Mass Spectrometry, Methods, Reagents and Kits
IL248149B (en) * 2016-09-29 2020-03-31 Garti Nissim Dilutable formulations of cannbinoids and processes for their preparation
JP7225103B2 (ja) * 2016-10-11 2023-02-20 ジービーエス グローバル バイオファーマ,インコーポレイテッド 神経変性疾患を処置するためのカンナビノイド含有複合混合物
WO2018118197A1 (en) * 2016-12-21 2018-06-28 Richard Postrel Healthier aging in domesticated animals
CN110997006A (zh) * 2017-05-08 2020-04-10 因美制药公司 眼部药物递送制剂
WO2018205038A1 (en) * 2017-05-12 2018-11-15 Tetra Bio-Pharma Inc. Compositions comprising cannabinoids and terpenes useful in the treatment of cancer and vascular ocular disorders via inhibition of hedgehog signalling
US20170348277A1 (en) * 2017-08-02 2017-12-07 Bryan Ray Ruiz Cannabinoid formulation including a vasodilator and ocular delivery of the same

Also Published As

Publication number Publication date
JP7633179B2 (ja) 2025-02-19
AU2020261515B2 (en) 2025-10-23
EP3958856A1 (en) 2022-03-02
SG11202111809XA (en) 2021-11-29
CA3134764A1 (en) 2020-10-29
US20230043428A1 (en) 2023-02-09
IL287536A (en) 2021-12-01
EP3958856A4 (en) 2023-01-25
IL287536B2 (en) 2026-03-01
WO2020215164A1 (en) 2020-10-29
MX2021012960A (es) 2022-01-04
AU2020261515A1 (en) 2021-11-18
CN114007603A (zh) 2022-02-01
IL287536B1 (en) 2025-11-01
JP2022530471A (ja) 2022-06-29

Similar Documents

Publication Publication Date Title
US12357604B2 (en) Topical formulations of cannabinoids and use thereof in the treatment of pain
JP7633179B2 (ja) 神経保護のためのカンナビノイドの組成物及び使用方法
Crooke et al. Update in glaucoma medicinal chemistry: emerging evidence for the importance of melatonin analogues
EP2852383A2 (en) Methods for drug screen using zebrafish model and the compounds screened thereform
WO2017053638A1 (en) Compounds and compositions for the treatment of ocular disorders
JP2004518612A (ja) インドール誘導体を用いて眼圧を下降させる方法
US9254287B2 (en) Therapeutic formulation and methods of treatment
KR20070040326A (ko) 백내장, 황반 변성 및 다른 안과 질환의 개선
KR20130122958A (ko) 망막의 질환을 치료하기 위한 방법
Saxena et al. Pharmacotherapy of glaucoma
IL259562A (en) Aminophosphinic derivatives for preventing and treating eye pain
ES2764654T3 (es) Combinaciones de prostaglandinas y donantes de óxido nítrico
CN117136050A (zh) 用于使用大麻素治疗神经元病症的组合物和方法
JP7834370B2 (ja) 緑内障の治療のためのカルパイン-2選択的阻害剤化合物
CN117279653A (zh) 用于治疗眼部疾病和病症的化合物
WO2010056710A1 (en) Compositions and methods for treating eye diseases
WO2025090133A1 (en) Compositions and methods for use of cannabinol compounds in neuroprotection
CA2888984A1 (en) Methods for treating eye disorders
US20080318939A1 (en) Methods for treating ophthalmic disorders
WO2025090587A1 (en) Cannabinoids compounds and their use in the treatment of neuronal disorders
JP2023547412A (ja) 眼疾患の治療
HK1241269B (en) Combinations of prostaglandins and nitric oxide donors
Kobayashi et al. 152. Neuroprotection Organizing Section: PH Contributing Section: RC
HK1241269A1 (en) Combinations of prostaglandins and nitric oxide donors
CA2369126A1 (en) Use of ap-1 activators to treat glaucoma and ocular hypertension

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PE0801 Dismissal of amendment

St.27 status event code: A-2-2-P10-P12-nap-PE0801

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000